Last reviewed · How we verify

Neonatal Hemorrhagic Disease — Treatment Landscape & Competitive Intelligence

Neonatal Hemorrhagic Disease (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Neonatal Hemorrhagic Disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
phytomenadione phytomenadione Instituto Mexicano del Seguro Social Alpha-synuclein
Phylloquinone Phylloquinone Guy's and St Thomas' NHS Foundation Trust Alpha-synuclein

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Guy's and St Thomas' NHS Foundation Trust · 1 drug in Neonatal Hemorrhagic Disease
  2. Instituto Mexicano del Seguro Social · 1 drug in Neonatal Hemorrhagic Disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Neonatal Hemorrhagic Disease:

Cite this brief

Drug Landscape (2026). Neonatal Hemorrhagic Disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neonatal-hemorrhagic-disease. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing